Pay in 4 interest-free payments of $6.64 Learn more
Ships within 48 hours · Estimated delivery Nov 2 - Nov 7
26, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced detailed results from ACHIEVE-3, the first head-to-head Phase 3 trial evaluating the safety and efficacy of orforglipron, a small molecule oral GLP-1 without food or water restrictions, compared with oral semaglutide in adults with type 2 diabetes inadequately controlled with metformin
They are widely recognized for their ability to curb appetite, support blood sugar control, and help patients lose weight more effectively than diet and exercise alone
decreased cell proliferation and DNA synthesis
M., Aliesky, H., Banuelos, B., Hee, S
Media coverage overlap
US$ 23.52
US$ 21.68
US$ 21.60
US$ 24.81
US$ 21.76
US$ 21.99
![Bump in the Night [Innistrad] SPA Conversión](https://cdn.shopify.com/s/files/1/0268/5285/1798/products/5c3ec389-a267-484f-994d-4a29ef494eb1.jpg?v=1571894130)
